	IPE						
TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT SEP 1 1 2006 (Under 37 CFR 1.97(b) or 1.97(c)) Docket No. RLL-347US							
In the A	Application of	: KUMAR et al.					
Appli	cation No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/549,821 / Unknown 26815 Unknown 3659							
Title:	PROCESS F		TION OF 7-AMINO (P-HYDR	ROXYPHENYGI	LYCLYAMIDO)	СЕРНЕМ	
			Address to: Commissioner for Pate P.O. Box 1450 Alexandria, VA 22313-1				
			37 CFR 1.97(b)				
1. 🛚	The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
			37 CFR 1.97(c)				
2.	The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
	☐ the s	statement specified in	n 37 CFR 1.97(e);				
OR							
☐ the fee set forth in 37 CFR 1.17(p).							

AL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) RLL-347US **%**e Application KUMAR et al. Application No. Filing Date Examiner Customer No. **Group Art Unit** Confirmation No. 10/549,821 Unknown 26815 Unknown 3659 Title: PROCESS FOR THE PREPARATION OF 7-AMINO (P-HYDROXYPHENYGLYCLYAMIDO) CEPHEM **COMPOUNDS** Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of is attached. ☑ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below. Charge the amount of Credit any overpayment. Charge any additional fee required. □ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Certificate of Transmission by Facsimile* Certificate of Mailing by First Class Mail I hereby certify that this correspondence is being deposited I certify that this document and authorization to charge deposit with the United States Postal Service with sufficient postage account is being facsimile transmitted to the United States as first class mail in an envelope addressed to Patent and Trademark Office (Fa "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on September 5, 2006 (Date) Signature Signature of Person Mailing Correspondence Michelle Morgan Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Certificate *This certificate may only be used if paying by deposit account. Dated: September 5, 2006 William D. Hare, Esq. Reg. No. 44,739 Customer No. 26,815

CC:

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-347US | Serial

Serial No.: 10/549,821

Applicants: KUMAR et al.

Filed: 9/20/2005

Group:

S. C.	100M		U.S. P	ATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	3,489,752	1/13/1970	Crast, Jr.	260	243	
	A2	3,867,380	2/18/1975	Dunn et al.	260	243	
	A3	3,899,394	8/12/1975	Willner <i>et al</i> .	195	29	
	A4	3,940,354	2/24/1976	Martel et al.	260	243	
	A5	3,988,450	10/26/1976	James	424	246	
	A6	4,139,702	2/13/1979	Broggi <i>et al.</i>	544	27	
	A7	4,148,817	4/10/1979	Wright	260	448.8	
	A8	4,504,657	3/12/1985	Bouzard <i>et al.</i>	544	30	
	A9	4,520,022	5/28/1985	Hoshi et al.	514	200	
- 4	A10	4,694,079	9/15/1987	Crast, Jr.	540	215	
			FOREIGN	N PATENT DOCUMENTS	<u> </u>		
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	GB 1,240,687	7/28/1971	Great Britain	C07D	99/24	[
	B2	JP 57-185291	11/15/1982	Japan	C07D	501/06	Abstract
	В3	WO 04/035593	4/29/2004	PCT	C07D	501/06	
	B4	WO 04/039812	5/13/2004	PCT	C07D	501/04	
		OTHER DOCUME	NTS (Includ	ding Author, Title, Date, P	ertinent Pa	ges, Etc.)	<u> </u>
	C1	C1 Kleemann, A.; Engel, J., <i>Pharmaceutical Substances; Synthesis, Patents, Application; A-M, 4th ed,</i> pages 368-371, 376-377, and 396-398 (2001) C2 Kempermann et al., "Synthesis of Cephalosporin-Type Antibiotics by Coupling of their β-Lactam Nucleus and Racemic Amino Acid Side Chains Using a Clathration-Induced Asymmetric Transformation", <i>European Journal of Organic Chemistry</i> , 2001(10):1817-1820 (2001)					
	C2						

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Docket No.: RLL-347US	Serial No.: 10/549,821		
INFORMATION DISCLOSURE CITATION	Applicants: KUMAR et al.			
	Filed: 9/20/2005	Group:		

С	,S	Huang et al., "Synthesis of Cefadroxil", <i>Chinese Journal of Pharmaceuticals</i> , <u>21</u> (8):343-345 (1990)
С	34	Castellvi et al., "Highly catalytic species in the formation of symmetrical anhydrides and mixt anhydrides", <i>Afinidad</i> , 43:421-424 (1986)

EXAMINER DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.